283 related articles for article (PubMed ID: 23443805)
21. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma.
Huynh H; Chow PK; Tai WM; Choo SP; Chung AY; Ong HS; Soo KC; Ong R; Linnartz R; Shi MM
J Hepatol; 2012 Mar; 56(3):595-601. PubMed ID: 22027573
[TBL] [Abstract][Full Text] [Related]
22. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
[TBL] [Abstract][Full Text] [Related]
23. Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo.
Boichuk S; Galembikova A; Dunaev P; Micheeva E; Valeeva E; Novikova M; Khromova N; Kopnin P
Molecules; 2018 Oct; 23(10):. PubMed ID: 30326595
[TBL] [Abstract][Full Text] [Related]
24. Silencing of FGFR4 could influence the biological features of gastric cancer cells and its therapeutic value in gastric cancer.
Ye Y; Jiang D; Li J; Wang M; Han C; Zhang X; Zhao C; Wen J; Kan Q
Tumour Biol; 2016 Mar; 37(3):3185-95. PubMed ID: 26432329
[TBL] [Abstract][Full Text] [Related]
25. Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion.
Kawano S; Kawada MI; Fukushima S; Arai Y; Shibata T; Miyano SW
Anticancer Res; 2024 Jun; 44(6):2393-2406. PubMed ID: 38821585
[TBL] [Abstract][Full Text] [Related]
26. Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398.
Datta J; Damodaran S; Parks H; Ocrainiciuc C; Miya J; Yu L; Gardner EP; Samorodnitsky E; Wing MR; Bhatt D; Hays J; Reeser JW; Roychowdhury S
Mol Cancer Ther; 2017 Apr; 16(4):614-624. PubMed ID: 28255027
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of FGFR2-Signaling Attenuates a Homology-Mediated DNA Repair in GIST and Sensitizes Them to DNA-Topoisomerase II Inhibitors.
Sergei B; Pavel D; Aigul G; Firyuza B; Ilmira N; Ilshat M; Aida A; Refat K; Natalia A; Elena S; Vera G
Int J Mol Sci; 2020 Jan; 21(1):. PubMed ID: 31948066
[TBL] [Abstract][Full Text] [Related]
28. The FGFR Inhibitor NVP-BGJ398 Induces NSCLC Cell Death by Activating Caspase-dependent Pathways as well as Caspase-independent Apoptosis.
Göke A; Göke R; Ofner A; Herbst A; Lankat-Buttgereit B
Anticancer Res; 2015 Nov; 35(11):5873-9. PubMed ID: 26504010
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of FGFR Signaling Partially Rescues Hypophosphatemic Rickets in HMWFGF2 Tg Male Mice.
Xiao L; Du E; Homer-Bouthiette C; Hurley MM
Endocrinology; 2017 Oct; 158(10):3629-3646. PubMed ID: 28938491
[TBL] [Abstract][Full Text] [Related]
30. FGFR2 as a molecular target in endometrial cancer.
Byron SA; Pollock PM
Future Oncol; 2009 Feb; 5(1):27-32. PubMed ID: 19243295
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.
Krook MA; Lenyo A; Wilberding M; Barker H; Dantuono M; Bailey KM; Chen HZ; Reeser JW; Wing MR; Miya J; Samorodnitsky E; Smith AM; Dao T; Martin DM; Ciombor KK; Hays J; Freud AG; Roychowdhury S
Mol Cancer Ther; 2020 Mar; 19(3):847-857. PubMed ID: 31911531
[TBL] [Abstract][Full Text] [Related]
32. Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells.
Grygielewicz P; Dymek B; Bujak A; Gunerka P; Stanczak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K; Zdzalik D
Gastric Cancer; 2016 Jan; 19(1):53-62. PubMed ID: 25407459
[TBL] [Abstract][Full Text] [Related]
33. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
[TBL] [Abstract][Full Text] [Related]
34. FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro.
Künstlinger H; Fassunke J; Schildhaus HU; Brors B; Heydt C; Ihle MA; Mechtersheimer G; Wardelmann E; Büttner R; Merkelbach-Bruse S
Oncotarget; 2015 Aug; 6(24):20215-30. PubMed ID: 26036639
[TBL] [Abstract][Full Text] [Related]
35. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
Tai WT; Cheng AL; Shiau CW; Liu CY; Ko CH; Lin MW; Chen PJ; Chen KF
Mol Cancer Ther; 2012 Feb; 11(2):452-63. PubMed ID: 22180308
[TBL] [Abstract][Full Text] [Related]
36. Polyclonal Secondary
Goyal L; Saha SK; Liu LY; Siravegna G; Leshchiner I; Ahronian LG; Lennerz JK; Vu P; Deshpande V; Kambadakone A; Mussolin B; Reyes S; Henderson L; Sun JE; Van Seventer EE; Gurski JM; Baltschukat S; Schacher-Engstler B; Barys L; Stamm C; Furet P; Ryan DP; Stone JR; Iafrate AJ; Getz G; Porta DG; Tiedt R; Bardelli A; Juric D; Corcoran RB; Bardeesy N; Zhu AX
Cancer Discov; 2017 Mar; 7(3):252-263. PubMed ID: 28034880
[TBL] [Abstract][Full Text] [Related]
37. FGF7-FGFR2 autocrine signaling increases growth and chemoresistance of fusion-positive rhabdomyosarcomas.
Milton CI; Selfe J; Aladowicz E; Man SYK; Bernauer C; Missiaglia E; Walters ZS; Gatz SA; Kelsey A; Generali M; Box G; Valenti M; de Haven-Brandon A; Galiwango D; Hayes A; Clarke M; Izquierdo E; Gonzalez De Castro D; Raynaud FI; Kirkin V; Shipley JM
Mol Oncol; 2022 Mar; 16(6):1272-1289. PubMed ID: 34850536
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation.
Byron SA; Gartside MG; Wellens CL; Mallon MA; Keenan JB; Powell MA; Goodfellow PJ; Pollock PM
Cancer Res; 2008 Sep; 68(17):6902-7. PubMed ID: 18757403
[TBL] [Abstract][Full Text] [Related]
39. Targeting FGFR with BGJ398 in Breast Cancer: Effect on Tumor Growth and Metastasis.
Sahores A; May M; Sequeira GR; Fuentes C; Jacobsen B; Lanari C; Lamb CA
Curr Cancer Drug Targets; 2018; 18(10):979-987. PubMed ID: 29237381
[TBL] [Abstract][Full Text] [Related]
40. Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma.
Hanes R; Munthe E; Grad I; Han J; Karlsen I; McCormack E; Meza-Zepeda LA; Stratford EW; Myklebost O
Cells; 2019 Feb; 8(2):. PubMed ID: 30795553
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]